GAITHERSBURG, Md., April 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Cynthia N. Oliver, Ph.D. to the position of Senior Vice President, Process Development Operations, effective April 8, 2014. Dr. Oliver will be responsible for all process development activities, with a specific focus on the company’s RSV F-protein nanoparticle, seasonal influenza and pandemic influenza vaccine candidates.
Help employers find you! Check out all the jobs and post your resume.
